Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus Vaccines
Study findings from University of Pennsylvania provide new insights into hepatitis C virus vaccines
December 31st, 2008
New research, 'Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine,' is the subject of a report. "Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals," scientists writing in the journal Vaccine report. "It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making...
Source: Vaccine Weekly (2008-12-31)
|
